INSERTS

Views:
 
Category: Education
     
 

Presentation Description

No description available.

Comments

By: stutisharma (23 month(s) ago)

Hello sir, you have made a wonderful presentation on inserts. I want to request you that can you please send me this presentation on my mail as it will be really very useful for me. I m doing my M.Pharmacy in pharmaceutics (1st year). This my mail id - stutisharma6@gmail.com

Presentation Transcript

A SEMINAR ON INSERTS : 

A SEMINAR ON INSERTS PREPARED BY:- NIRANJAN UPADHYAY. M.PHARMA.(1ST YR) PHARMACEUTICS NIMS UNIVERSITY

INSERTS : 

INSERTS Inserts are devices prepared from solid and semisolid consistency which are inserted in to body. Therapeutic action. Controlled rate. Shaped according to need. EXAMPLE:- 1) Opthalmic Insert. 2) Intravaginal Insert. 3) Intrauterine Insert.

Opthalmic insert. : 

Opthalmic insert. Eye require localized administration of drugs in to ocular cavity. Most prescribed dosage form is eye drops. Drained or cleaned. Required to maintained sustained or continuous level of medication.

Desired criteria for ocular inserts. : 

Desired criteria for ocular inserts. Comfort. Ease of handling. Non interference with vision and oxygen permeability. Reproductibility of release kinetics. Sterility. Stability. Ease of manufacturing.

Types of ophthlamic inserts. : 

Types of ophthlamic inserts.

A) Non-Erodible : 

A) Non-Erodible 1.Ocusert: - Developed by Alza Corporation, - Flat, elliptical, flexible ocular insert, - Release Rate:20-40mg/hr for 7day.

Slide 7: 

Annular ring : Impregnated with Ti02 : For Visibility. Marketed example

2) Contact Lens : : 

2) Contact Lens : Types:- 1) Rigid contact lenes. 2) Semi solid contact lenes. 3) Elastomeric contact lenes. Most of Drug Release : within 1st 30 Min. Release rate is up to : 180 hr. Used in corneal woznel healing.

Marketed example : 

Marketed example

B) Erodible Inserts : 

B) Erodible Inserts Lacrisert: Sterile, Rod Shaped device. Composition: HPC without preservative. Weight:5mg, Dimension:Diameter:12.5mm, Length:3.5mm Use:-Dry eye treatment, Keratitis Sica. Inserted in to inferior fornix form hydrophillic film with tear.

Marketed example : 

Marketed example AstraZeneca Aton Pharma Inc

2) SODI (Soluble Ocular Drug Insert) : 

2) SODI (Soluble Ocular Drug Insert) Shape- 0val Composition : Acryl amide, Vinyl Pyrolidone, Ethylacrylate. Weight 15-16 mg. In 10-15 sec Softens; In 10-15 min. turns in Viscous Liquids; After 30-60min. Becomes Polymeric Solution.

3)Minidisc: : 

3)Minidisc: It is made up of small disc with Convex front & Concave back surface in contact with eye ball. 4-5mm in diameter. Composition : Silicon based pre polymer. Hydrophilic or Hydrophobic. Drug release for 170 hr.

C) Nanoparticle: : 

C) Nanoparticle:

D) Liposome : 

D) Liposome

2.Intravaginal Insert. : 

2.Intravaginal Insert. It is used for delivery of contraceptive steroid hormones.It is of two types. a)Matrix diffusion controlled devices. b)Dissolution controlled devices. b)Dissolution controlled devices. Medicament release time-21 days. Drug reservoir- dispersed progestin and estrogen in an aqueous solution of PEG-400.

Slide 17: 

Polymer- silicone polymer. No first- pass effect. Improved bioavailability. Less dose is requried. Advantages-

Marketed example : 

Marketed example

3.Intrauterine insert. : 

3.Intrauterine insert. It is used for fertility control. Developed to produce effective contraception for 12 months or more. It is two types A) Copprer medicated IUD. B) Progesterone releasing IUD.

A) Copper medicated IUD. : 

A) Copper medicated IUD. It consist of polypropylene or polyethylene plastic support. T shaped with certain amount of wire wound around them. Copper released slowly in body cavity by oxidation. Device is effective for more than 3 years.

Example : 

Example

b) Progesterone releasing IUD. : 

b) Progesterone releasing IUD. T shaped polyethylene device with progesterone reservoir dispersed in a silicone polymer. Rate controlling membrane of ethylene-vinyl acetate. Device releases progesterone at a rate of 60 µg/day for one year.

Marketed example : 

Marketed example

REFERENCES : 

REFERENCES N.K.Jain, Advances in Controlled & Novel Drug Delivery, CBS Publication, & distributor, New Delhi, pg No.219-223. Remington & Gennaro ; The Science & Practice Of Pharmacy. Mack Publication Company. Easton, Pennsylvania. Pg. No. 1563-1567. www.vision-care-guide.com www.google/images/eye/anatomy& physiology